
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million.
Research and development expenses were $5.1 million for the first quarter of 2022, including stock-based compensation of $0.5 million. General and administrative expenses were $3.8 million in the first quarter of 2022, including stock-based compensation expense of $0.6 million.